Nancy Miller-Rich
Directeur/Membre du Conseil chez ALDEYRA THERAPEUTICS, INC.
Fortune : - $ au 30/04/2024
Profil
Ms. Nancy Miller-Rich is a Chairman at BioTheryX, Inc., an Independent Director at 4D Molecular Therapeutics, Inc., an Independent Director at Aldeyra Therapeutics, Inc., a Chief Executive Officer at Miller-Rich Associates LLC, an Executive Chairman at Altum Pharmaceuticals, Inc. and an Independent Director at Attralus, Inc. She is on the Board of Directors at 4D Molecular Therapeutics, Inc., Aldeyra Therapeutics, Inc., Global Alliance for TB Drug Development, Helio Vision, Inc. and Attralus, Inc. Ms. Miller-Rich was previously employed as an Independent Director by Kadmon Holdings, Inc., a Co-Founder by Ten63 Therapeutics, Inc., an Independent Director by Intercept Pharmaceuticals, Inc., an Independent Non-Executive Director by UDG Healthcare Ltd.
(Dublin), a SVP-Global Human Health Business Development by Merck & Co., Inc., and a SVP-Global Human Health Business Development by Schering-Plough Corp.
She received her undergraduate degree from Ithaca College.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 21/05/2024 | 0 ( -.--% ) | - $ | 30/04/2024 | |
| 09/04/2024 | 0 ( -.--% ) | - $ | 30/04/2024 |
Postes actifs de Nancy Miller-Rich
| Sociétés | Poste | Début |
|---|---|---|
| ALDEYRA THERAPEUTICS, INC. | Directeur/Membre du Conseil | 13/01/2020 |
| 4D MOLECULAR THERAPEUTICS, INC. | Directeur/Membre du Conseil | 18/11/2020 |
Global Alliance for TB Drug Development
 Global Alliance for TB Drug Development Pharmaceuticals: GenericHealth Technology Global Alliance for TB Drug Development operates as a not-for-profit organization dedicated to the discovery and development of tuberculosis drugs. It builds partnerships between the public, private, academic, and philanthropic sectors to drive the development of new products for underserved markets. The company was founded in February 2000 and is headquartered in New York , NY. | Directeur/Membre du Conseil | 06/03/2018 |
Altum Pharmaceuticals, Inc.
 Altum Pharmaceuticals, Inc. Pharmaceuticals: GenericHealth Technology Altum Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in the clinical and commercial development of novel healthcare products for the treatment of women's gynecological neoplasia, autoimmune disorders, Hypercalcemia of Malignancy, Skeletal Related Events and Osteoporosis diseases. The company was founded in 2016 and is headquartered in Vancouver, Canada. | Président | - |
Attralus, Inc.
 Attralus, Inc. Pharmaceuticals: MajorHealth Technology Attralus, Inc. operates as a biopharmaceutical company. The firm focuses on illuminating the systemic nature of amyloidosis and creating transformative medicines to improve the lives of patients. The company was founded by Jonathan Wall in 2019 and is headquartered in San Francisco, CA. | Directeur/Membre du Conseil | - |
| Miller-Rich Associates LLC | Directeur Général | 01/01/2017 |
BioTheryX, Inc.
 BioTheryX, Inc. Pharmaceuticals: MajorHealth Technology BioTheryX, Inc. pengages in the development of clinical drugs. It focuses on the restoration of protein homeostasis, including protein degradation and modulation, and multi-kinase inhibition. The company was founded by David I. Stirling and Lawrence Zaslow in 2007 and is headquartered in Chappaqua, NY. | Président | 23/02/2022 |
Helio Vision, Inc.
 Helio Vision, Inc. Pharmaceuticals: MajorHealth Technology Helio Vision, Inc. operates as a biotechnology company. It develops a therapy for fibroproliferative disorders that lead to abnormal scarring and blindness after retina surgery. The company was founded by Josef H. von Rickenbach, Dean Eliott and Tomasz P. Stryjewski in 2016 and is headquartered in Waltham, MA. | Directeur/Membre du Conseil | - |
Anciens postes connus de Nancy Miller-Rich
| Sociétés | Poste | Fin |
|---|---|---|
| INTERCEPT PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 08/11/2023 |
| ░░░ ░░░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░░░░░░ ░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░░ ░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░░░░░░░░░ | ░░░░░░░░░ | - |
Formation de Nancy Miller-Rich
| Ithaca College | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| ALDEYRA THERAPEUTICS, INC. | Health Technology |
| INTERCEPT PHARMACEUTICALS, INC. | Health Technology |
| 4D MOLECULAR THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 10 |
|---|---|
Schering-Plough Corp.
 Schering-Plough Corp. Pharmaceuticals: MajorHealth Technology Schering Plough Corp. manufactures and sells pharmaceuticals, consumer and animal health care products. The firm discovers, develops, manufactures and markets advanced drug therapies. The company is headquartered in Kenilworth, NJ. | Health Technology |
Global Alliance for TB Drug Development
Global Alliance for TB Drug Development Pharmaceuticals: GenericHealth Technology Global Alliance for TB Drug Development operates as a not-for-profit organization dedicated to the discovery and development of tuberculosis drugs. It builds partnerships between the public, private, academic, and philanthropic sectors to drive the development of new products for underserved markets. The company was founded in February 2000 and is headquartered in New York , NY. | Health Technology |
BioTheryX, Inc.
BioTheryX, Inc. Pharmaceuticals: MajorHealth Technology BioTheryX, Inc. pengages in the development of clinical drugs. It focuses on the restoration of protein homeostasis, including protein degradation and modulation, and multi-kinase inhibition. The company was founded by David I. Stirling and Lawrence Zaslow in 2007 and is headquartered in Chappaqua, NY. | Health Technology |
Kadmon Holdings, Inc.
 Kadmon Holdings, Inc. BiotechnologyHealth Technology Kadmon Holdings, Inc. is a biopharmaceutical company, which engages in discovering, developing, and commercializing small molecules and biologics to address unmet medical need. The company's clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies. The firms late-stage product candidate KD025, which is an orally administered selective inhibitor of Rho-associated coiled-coil kinase engages in development for the treatment of inflammatory and fibrotic diseases. The firm's a pivotal clinical trial of KD025 is underway in chronic graft-versus-host disease (cGVHD), as well as a Phase 2 clinical trial in systemic sclerosis. It is also developing next-generation immuno-oncology therapies, specifically IL-15 containing fusion proteins, for the treatment of cancer. The company's lead I-O product candidate, KD033, is an anti-PD-L1/IL-15 fusion protein. Kadmon was founded by Steven N. Gordon in September 2010 and is headquartered in New York, NY. | Health Technology |
UDG Healthcare Ltd. (Dublin)
 UDG Healthcare Ltd. (Dublin) Miscellaneous Commercial ServicesCommercial Services UDG Healthcare Plc engages in the supply and distribution of pharmaceutical and medical products. It operates through the following segments: Ashfield, Sharp, and Aquilant. The Ashfield segment provides commercialization services for the pharmaceutical and healthcare industry. The Sharp segment offers contract packaging and clinical trial packaging services. The Aquilant segment involves. outsourced sales, marketing, distribution, and engineering services to the medical and scientific sectors. The company was founded in 1948 and is headquartered in Dublin, Ireland. | Commercial Services |
Helio Vision, Inc.
Helio Vision, Inc. Pharmaceuticals: MajorHealth Technology Helio Vision, Inc. operates as a biotechnology company. It develops a therapy for fibroproliferative disorders that lead to abnormal scarring and blindness after retina surgery. The company was founded by Josef H. von Rickenbach, Dean Eliott and Tomasz P. Stryjewski in 2016 and is headquartered in Waltham, MA. | Health Technology |
Altum Pharmaceuticals, Inc.
Altum Pharmaceuticals, Inc. Pharmaceuticals: GenericHealth Technology Altum Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in the clinical and commercial development of novel healthcare products for the treatment of women's gynecological neoplasia, autoimmune disorders, Hypercalcemia of Malignancy, Skeletal Related Events and Osteoporosis diseases. The company was founded in 2016 and is headquartered in Vancouver, Canada. | Health Technology |
TEN63 Therapeutics
 TEN63 Therapeutics Pharmaceuticals: MajorHealth Technology TEN63 Therapeutics provides drug development services. The American company was founded by Nancy Miller-Rich, Marcel Frenkel, Mark Hallen, Bruce Donald. Marcel Frenkel has been the CEO since incorporation. | Health Technology |
Attralus, Inc.
Attralus, Inc. Pharmaceuticals: MajorHealth Technology Attralus, Inc. operates as a biopharmaceutical company. The firm focuses on illuminating the systemic nature of amyloidosis and creating transformative medicines to improve the lives of patients. The company was founded by Jonathan Wall in 2019 and is headquartered in San Francisco, CA. | Health Technology |
| Miller-Rich Associates LLC |